Your browser doesn't support javascript.
loading
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Sam, Johannes; Colombetti, Sara; Fauti, Tanja; Roller, Andreas; Biehl, Marlene; Fahrni, Linda; Nicolini, Valeria; Perro, Mario; Nayak, Tapan; Bommer, Esther; Schoenle, Anne; Karagianni, Maria; Le Clech, Marine; Steinhoff, Nathalie; Klein, Christian; Umaña, Pablo; Bacac, Marina.
Afiliación
  • Sam J; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Colombetti S; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Fauti T; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Roller A; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Biehl M; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Fahrni L; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Nicolini V; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Perro M; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Nayak T; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Bommer E; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Schoenle A; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Karagianni M; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Le Clech M; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Steinhoff N; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Klein C; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Umaña P; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
  • Bacac M; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
Front Oncol ; 10: 575737, 2020.
Article en En | MEDLINE | ID: mdl-33330050
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2020 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2020 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza